Research & development
Driving scientific innovation to deliver the next generation of transformational medicines and vaccines for patients
We are a science-led global healthcare company. Our purpose is to help people do more, feel better, live longer.
We deliver our long-term priorities of Innovation, Performance and Trust through each of our three businesses which discover, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.
Our Pharmaceuticals research is focused on science related to the immune system, the use of human genetics, and the application of advanced technologies such as functional genomics, artificial intelligence and machine learning. Our approach is driven by the “multiplier effect” of Science x Technology x Culture. It will help us to accelerate the pace at which we develop and deliver transformational medicines, prioritising those molecules with a higher probability of success and terminating less promising programmes. It also enables us to increase our focus on specialty medicines in areas such as oncology
In our Vaccines business, we balance our focus on a robust pipeline with the active life-cycle management of our existing vaccines, seeking to protect more people through expanding indications and delivering our vaccines to new geographies. Our Innovation ambition is to lead the industry by disrupting the discovery, development and manufacturing of vaccines. We will focus on accelerating key assets in our pipeline and looking at innovative technologies so that we can unlock potential in emerging fields. Using our industry-leading science, we will accelerate the delivery of our most promising assets to serve the greatest unmet medical need. We want to change the world with our science.
Our Consumer Healthcare R&D organization develops products in five categories: Oral Health, Pain Relief, Respiratory, Nutrition and Gastrointestinal and Skin Health. Our focus is on building a strong, competitive pipeline of consumer-led, science-based innovation. On 1 August 2019 we announced that we'd completed our transaction with Pfizer to combine our consumer healthcare businesses into a new world-leading Consumer Healthcare Joint Venture. Within three years of the closing of the transaction, we intend to separate the Joint Venture via a demerger. With our future intention to separate, the transaction also presents a clear pathway forward for us to create a new global Pharmaceuticals/Vaccines company, and a new world-leading Consumer Healthcare company. Find our more
Find out more information on our Global Website.
Key facts about R&D at GSK
Over 12,000 people working across our three global businesses
Our adjusted R&D investment in 2020
Our pipeline comprises 57 vaccines and medicines in development at FY 2020
Find out more
Responsible business is how we do business. Our purpose is to help people to do more, feel better, live longer.